Brief: Candel Therapeutics Reports Encouraging Initial Survival Data From Phase 2 Clinical Trial Of Can-2409 In Non-Small Cell Lung Cancer
26/09/2023 13:04
Sept 26 (Reuters) - Candel Therapeutics Inc CADL.O :
* CANDEL THERAPEUTICS REPORTS ENCOURAGING INITIAL SURVIVAL
DATA
FROM PHASE 2 CLINICAL TRIAL OF CAN-2409 IN NON-SMALL CELL LUNG
CANCER
* CANDEL THERAPEUTICS INC - TOPLINE OVERALL SURVIVAL DATA
EXPECTED IN Q2 2024
* CANDEL THERAPEUTICS REPORTS ENCOURAGING INITIAL SURVIVAL
DATA
FROM PHASE 2 CLINICAL TRIAL OF CAN-2409 IN NON-SMALL CELL LUNG
CANCER
* CANDEL THERAPEUTICS INC - INITIAL DATA SUGGESTS 12-MONTH
SURVIVAL IS CONSISTENT WITH AN INCREASED TAIL ON MATURING
SURVIVAL CURVE
Source text for Eikon: ID:nGNXbTfLFP
Further company coverage: CADL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec